EYLEA Drug Profile
✉ Email this page to a colleague
Summary for Tradename: EYLEA
| High Confidence Patents: | 13 |
| Applicants: | 1 |
| BLAs: | 2 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for EYLEA |
Recent Litigation for EYLEA
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc. | 2024-09-24 |
| Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc. | 2024-06-20 |
| Novartis Pharma AG v. Regeneron Pharmaceuticals, Inc. | 2023-01-05 |
PTAB Litigation
| Petitioner | Date |
|---|---|
| Regeneron Pharmaceuticals, Inc. et al. | 2021-04-16 |
| Regeneron Pharmaceuticals, Inc. | 2020-07-16 |
| Regeneron Pharmaceuticals, Inc. et al. | 2020-07-16 |
Pharmacology for EYLEA
| Mechanism of Action | Vascular Endothelial Growth Factor Inhibitors |
| Established Pharmacologic Class | Vascular Endothelial Growth Factor Inhibitor |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for EYLEA Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for EYLEA Derived from Company Disclosures
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | EYLEA | aflibercept | Injection | 125387 | ⤷ Sign Up | 2037-03-28 | Company disclosures |
| Regeneron Pharmaceuticals, Inc. | EYLEA | aflibercept | Injection | 125387 | ⤷ Sign Up | 2038-10-12 | Company disclosures |
| Regeneron Pharmaceuticals, Inc. | EYLEA | aflibercept | Injection | 125387 | ⤷ Sign Up | 2039-04-29 | Company disclosures |
| Regeneron Pharmaceuticals, Inc. | EYLEA | aflibercept | Injection | 125387 | ⤷ Sign Up | 2039-09-25 | Company disclosures |
| Regeneron Pharmaceuticals, Inc. | EYLEA | aflibercept | Injection | 125387 | ⤷ Sign Up | 2040-01-10 | Company disclosures |
| Regeneron Pharmaceuticals, Inc. | EYLEA | aflibercept | Injection | 125387 | ⤷ Sign Up | 2041-06-21 | Company disclosures |
| Regeneron Pharmaceuticals, Inc. | EYLEA | aflibercept | Injection | 125387 | ⤷ Sign Up | Company disclosures | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for EYLEA Derived from Patent Text Search
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | EYLEA | aflibercept | Injection | 125387 | ⤷ Sign Up | 2032-05-15 | Patent claims search |
| Regeneron Pharmaceuticals, Inc. | EYLEA | aflibercept | Injection | 125387 | ⤷ Sign Up | 2034-11-25 | Patent claims search |
| Regeneron Pharmaceuticals, Inc. | EYLEA | aflibercept | Injection | 125387 | ⤷ Sign Up | 2036-04-22 | Patent claims search |
| Regeneron Pharmaceuticals, Inc. | EYLEA | aflibercept | Injection | 125387 | ⤷ Sign Up | 2034-03-18 | Patent claims search |
| Regeneron Pharmaceuticals, Inc. | EYLEA | aflibercept | Injection | 125387 | ⤷ Sign Up | 2036-04-22 | Patent claims search |
| Regeneron Pharmaceuticals, Inc. | EYLEA | aflibercept | Injection | 125387 | ⤷ Sign Up | 2032-12-05 | Patent claims search |
| Regeneron Pharmaceuticals, Inc. | EYLEA | aflibercept | Injection | 125387 | ⤷ Sign Up | 2032-02-15 | Patent claims search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for EYLEA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 4723140 | ⤷ Sign Up |
| European Patent Office | 2944306 | ⤷ Sign Up |
| Russian Federation | 2009101226 | ⤷ Sign Up |
| South Korea | 20020019070 | ⤷ Sign Up |
| Israel | 172404 | ⤷ Sign Up |
| Hungary | E053612 | ⤷ Sign Up |
| Portugal | 2364691 | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for EYLEA
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 122013000041 | Germany | ⤷ Sign Up | PRODUCT NAME: AFLIBERCEPT; REGISTRATION NO/DATE: EU/1/12/797/001-002 20121122 |
| 20/2013 | Austria | ⤷ Sign Up | PRODUCT NAME: AFLIBERCEPT; REGISTRATION NO/DATE: EU/1/12/797/001 UND 002 20121122 |
| C201300026 | Spain | ⤷ Sign Up | PRODUCT NAME: AFLIBERCEPT; NATIONAL AUTHORISATION NUMBER: EU/1/12/797/001-002; DATE OF AUTHORISATION: 20121122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/12/797/001-002; DATE OF FIRST AUTHORISATION IN EEA: 20121122 |
| 92195 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: AFLIBERCEPT (EYLEA - ZALTRAP) |
| 300588 | Netherlands | ⤷ Sign Up | PRODUCT NAME: AFLIBERCEPT; REGISTRATION NO/DATE: EU/1/12/797/001-002 20121122 |
| SPC/GB13/028 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: AFLIBERCEPT; REGISTERED: UK EU/1/12/797/001 20121122; UK EU/1/12/797/002 20121122 |
| C01183353/01 | Switzerland | ⤷ Sign Up | VERTRETERLOESCHUNG |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
